Assignee
IMMATICS BIOTECHNOLOGIES GMBH
DE·699 granted patents·227 pending applications·4,925 citations·filing 2000–2025
Top patents by PatentIndex Score
926 records- 0199US11890334B2Personalized immunotherapy against several neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 6, 2024·8 cites·20 claims
- 0299US11826409B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Nov 28, 2023·6 cites·20 claims
- 0399US11786584B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 17, 2023·4 cites·20 claims
- 0499US11759507B2Personalized immunotherapy against several neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Sep 19, 2023·9 cites·20 claims
- 0599US11618774B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Apr 4, 2023·6 cites·20 claims
- 0699US11607446B2Personalized immunotherapy against several neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 21, 2023·14 cites·20 claims
- 0799US11529401B2Personalized immunotherapy against several neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Dec 20, 2022·14 cites·20 claims
- 0899US11529400B1Personalized immunotherapy against several neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Dec 20, 2022·14 cites·20 claims
- 0999US11524059B2Personalized immunotherapy against several neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Dec 13, 2022·14 cites·20 claims
- 1099US11498948B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Nov 15, 2022·4 cites·20 claims
- 1199US11479589B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Oct 25, 2022·4 cites·20 claims
- 1299US11466072B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 11, 2022·17 cites·20 claims
- 1399US11459371B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 4, 2022·6 cites·22 claims
- 1499US11440947B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 13, 2022·6 cites·20 claims
- 1599US11434274B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Sep 6, 2022·6 cites·20 claims
- 1699US11434273B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 6, 2022·6 cites·20 claims
- 1799US11414472B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Aug 16, 2022·3 cites·20 claims
- 1899US11414470B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 16, 2022·6 cites·20 claims
- 1999US11407808B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 9, 2022·12 cites·20 claims
- 2099US11407807B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 9, 2022·17 cites·20 claims
- 2199US11407798B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Aug 9, 2022·6 cites·20 claims
- 2299US11407810B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 9, 2022·6 cites·20 claims
- 2399US11407809B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 9, 2022·6 cites·20 claims
- 2499US11401319B2Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 2, 2022·3 cites·20 claims
- 2599US11370817B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jun 28, 2022·6 cites·20 claims
- 2699US11365234B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jun 21, 2022·12 cites·20 claims
- 2799US11365235B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jun 21, 2022·6 cites·20 claims
- 2899US11352401B1Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jun 7, 2022·4 cites·20 claims
- 2999US11332512B2Peptides and combination of peptides for use in immunotherapy against various tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted May 17, 2022·12 cites·20 claims
- 3099US11324812B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted May 10, 2022·11 cites·20 claims
- 3199US11298404B2Immunotherapy against several tumors including gastrointestinal and gastric cancerIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Apr 12, 2022·14 cites·20 claims
- 3299US11292821B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Apr 5, 2022·5 cites·20 claims
- 3399US11279741B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 22, 2022·7 cites·20 claims
- 3499US11279740B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 22, 2022·4 cites·20 claims
- 3599US11278571B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 22, 2022·8 cites·20 claims
- 3699US11273200B2Immunotherapy against several tumors including gastrointestinal and gastric cancerIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 15, 2022·15 cites·20 claims
- 3799US11261224B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 1, 2022·5 cites·20 claims
- 3899US11246889B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 15, 2022·5 cites·20 claims
- 3999US11208434B2Immunotherapy against several tumors including neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Dec 28, 2021·14 cites·20 claims
- 4099US11155597B2Relaxin1 derived peptides for use in immunotherapyIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 26, 2021·17 cites·20 claims
- 4199US11136352B2Immunotherapy against several tumors including neuronal and brain tumorsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Oct 5, 2021·11 cites·20 claims
- 4299US11123370B2Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 21, 2021·4 cites·20 claims
- 4399US11077171B2Immunotherapy against several tumors including gastrointestinal and gastric cancerIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Aug 3, 2021·18 cites·20 claims
- 4499US11071773B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jul 27, 2021·8 cites·20 claims
- 4599US11071756B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 27, 2021·5 cites·20 claims
- 4699US11065315B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 20, 2021·12 cites·20 claims
- 4799US11058726B2Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 13, 2021·4 cites·20 claims
- 4899US11058754B2Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 13, 2021·14 cites·24 claims
- 4999US11027002B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jun 8, 2021·8 cites·20 claims
- 5099US11001616B2Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted May 11, 2021·5 cites·20 claims
Showing the top 50 of 926 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →